"These guidelines were produced by the World Health Organization (WHO), Department of Mental Health and Substance Abuse, in collaboration with the United Nations Office on Drugs and Crime (UNODC) a Guidelines Development Group of technical experts, and in consultation with the International Narcotics Control Board (INCB) secretariat and other WHO departments. WHO also wishes to acknowledge the financial contribution of UNODC and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to this project. " - p. iv

1. Scope and purpose -- 2. Method of formulating recommendations -- 3 Background -- 4. Guidelines for health systems at national and subnational levels -- 5. Programme level guidelines--for programme managers and clinical leaders -- 6. Patient level guidelines-- for clinicians -- Annex 1. Evidence profiles -- Annex 2. Dispensing, dosing and prescriptions -- Annex 3. ICD-10 codes for conditions covered in these guidelines -- Annex 4. Pharmacology of medicines available for the treatment of opioid dependence -- Annex 5. Drug interactions involving methadone and buprenorphine -- Annex 6. Alternatives for the treatment of opioid dependence not included in the current guidelines -- Annex 7. Methadone and buprenorphine and international drug control conventions -- Annex 8. Priorities for research -- Annex 9. Background papers prepared for technical expert meetings to inform guideline development -- Annex 10. Opioid withdrawal scales -- Annex 11. Summary of characteristics of selected psychoactive substances -- Annex 12. Prescribing guidelines -- Annex 13. Glossary